Trial Profile
Investigation of the Use of Nesiritide in Transplant-Eligible Management of Congestive Heart Failure-TMAC.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2014
Price :
$35
*
At a glance
- Drugs Nesiritide (Primary) ; Dobutamine; Milrinone
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms TMAC
- Sponsors Scios
- 04 Dec 2008 Additional trial identifier TMAC A051 reported by ClinicalTrials.gov.
- 14 May 2008 Status changed from in progress to discontinued.
- 28 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.